Differential effects of apelin-13 on lipid peroxidation and DNA oxidation in doxorubicin-treated rats: A preliminary study

Katarzyna Matusik; Katarzyna Kamińska; Kaja Kasarełło; Agnieszka Cudnoch-Jędrzejewska

doi:10.17305/bb.2025.13217

Authors

Katarzyna Matusik Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
Katarzyna Kamińska Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
Kaja Kasarełło Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
Agnieszka Cudnoch-Jędrzejewska Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland

DOI:

https://doi.org/10.17305/bb.2025.13217

Keywords:

Apelin-13, doxorubicin, oxidative stress

Abstract

Doxorubicin-induced cardiotoxicity is closely associated with oxidative stress (OS), and apelin-13 has been proposed as a potential cardioprotective peptide. However, its effects on specific oxidative stress (OS) markers remain poorly understood. This preliminary study aimed to evaluate the impact of apelin-13 on oxidative stress markers in rats chronically treated with doxorubicin (DOX). Male rats received DOX with or without apelin-13 (40 µg/kg body weight/day). The levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) and malondialdehyde (MDA) were measured as indicators of oxidative DNA damage and lipid peroxidation, respectively. The DOX treatment resulted in increased MDA levels, which were unaffected by apelin-13. Conversely, 8-OHdG levels decreased with DOX alone but returned to baseline levels in the presence of DOX and apelin-13. In conclusion, while apelin-13 did not mitigate DOX-induced lipid oxidative damage, it may selectively influence nuclear OS markers. This suggests a complex and context-dependent role of apelin-13 in modulating oxidative stress associated with DOX treatment.

Citations

Downloads

Download data is not yet available.

References

Zhang, Y.W., Shi, J., Li, Y.J., et al., Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz), 2009. 57(6): p. 435–445. https://doi.org/10.1007/s00005-009-0051-8

Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., et al., Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol, 2012. 52(6): p. 1213–1225. https://doi.org/10.1016/j.yjmcc.2012.03.006

Panda, P., Verma, H.K., Lakkakula, S., et al., Biomarkers of oxidative stress tethered to cardiovascular diseases. Oxid Med Cell Longev, 2022. 2022: p. 9154295. https://doi.org/10.1155/2022/9154295

Yu, X.H., Tang, Z.B., Liu, L.J., et al., Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta, 2014. 428: p. 1–8. https://doi.org/10.1016/j.cca.2013.09.001

Hamada, J., Baasanjav, A., Ono, N., et al., Possible involvement of downregulation of the apelin-APJ system in doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol, 2015. 308(8): p. H931–H941. https://doi.org/10.1152/ajpheart.00703.2013

Wang, X., Zhang, L., Feng, M., et al., The apelin-13 peptide protects the heart against apoptosis through the ERK/MAPK and PI3K/AKT signaling pathways. Research Square, 2020. https://doi.org/10.21203/rs.3.rs-42016/v2

Zhang, P., Yi, L.H., Meng, G.Y., et al., Apelin-13 attenuates cisplatin-induced cardiotoxicity through inhibition of ROS-mediated DNA damage and regulation of MAPKs and AKT pathways. Free Radic Res, 2017. 51(5): p. 449–459. https://doi.org/10.1080/10715762.2017.1313414

Duan, J., Cui, J., Yang, Z., et al., Neuroprotective effect of Apelin 13 on ischemic stroke by activating AMPK/GSK-3beta/Nrf2 signaling. J Neuroinflammation, 2019. 16(1): p. 24. https://doi.org/10.1186/s12974-019-1406-7

Xu, Z. and Z. Li, Experimental study on the role of Apelin-13 in alleviating spinal cord ischemia reperfusion injury through suppressing autophagy. Drug Des Devel Ther, 2020. 14: p. 1571–1581. https://doi.org/10.2147/DDDT.S241066